Michael Freeman
Stock Analyst at Raymond James
(2.38)
# 2,521
Out of 4,964 analysts
6
Total ratings
60%
Success rate
11.16%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Freeman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WVE Wave Life Sciences | Assumes: Outperform | $14 | $9.94 | +40.85% | 1 | Jun 11, 2025 | |
| TECX Tectonic Therapeutic | Reinstates: Outperform | $76 | $24.57 | +209.32% | 1 | Jun 11, 2025 | |
| DYN Dyne Therapeutics | Assumes: Outperform | $37 | $13.00 | +184.62% | 1 | Jun 11, 2025 | |
| IRON Disc Medicine | Reinstates: Strong Buy | $89 | $59.41 | +49.81% | 1 | Jun 11, 2025 | |
| RNA Avidity Biosciences | Initiates: Strong Buy | $65 | $45.27 | +43.58% | 1 | Jun 11, 2025 | |
| BHC Bausch Health Companies | Initiates: Market Perform | $8 | $7.30 | +9.59% | 1 | Jul 10, 2024 |
Wave Life Sciences
Jun 11, 2025
Assumes: Outperform
Price Target: $14
Current: $9.94
Upside: +40.85%
Tectonic Therapeutic
Jun 11, 2025
Reinstates: Outperform
Price Target: $76
Current: $24.57
Upside: +209.32%
Dyne Therapeutics
Jun 11, 2025
Assumes: Outperform
Price Target: $37
Current: $13.00
Upside: +184.62%
Disc Medicine
Jun 11, 2025
Reinstates: Strong Buy
Price Target: $89
Current: $59.41
Upside: +49.81%
Avidity Biosciences
Jun 11, 2025
Initiates: Strong Buy
Price Target: $65
Current: $45.27
Upside: +43.58%
Bausch Health Companies
Jul 10, 2024
Initiates: Market Perform
Price Target: $8
Current: $7.30
Upside: +9.59%